share_log

Preclinical Trial Results Confirm Targeting Type 2 Cannabinoid Receptors Helps Relieve Sepsis-Related Condition

Preclinical Trial Results Confirm Targeting Type 2 Cannabinoid Receptors Helps Relieve Sepsis-Related Condition

臨牀前試驗結果證實靶向2型大麻素受體有助於緩解膿毒症相關疾病
Benzinga Real-time News ·  2022/08/10 10:40
Tetra Bio-Pharma Inc. (OTCQB:TBPMF) (TSX:TBP) (FRA:JAM1) revealed positive preclinical results from live SARS-CoV-2 virus infection studies as well as a septic lung model, carried out by independent researchers.
利樂生物製藥公司。(OTCQB:TBPMF)(多倫多證券交易所:TBP)(法蘭克福證券交易所:JAM1)披露SARS-CoV-2病毒活體感染研究的臨牀前陽性結果以及由獨立研究人員進行的敗血癥肺模型。
These studies explored the potential of ARDS-003 to increase survival metrics following SARS-CoV-2 infection in the humanized ACE2 mouse model. Secondary outcomes evaluated ARDS-003 against an antiviral drug, a clinical standard of care therapeutic used for patients with COVID, in SARS-CoV-2 infected animals. Results indicate that compared to placebo, ARDS-003 dose dependently reduced signs of morbidity and mortality, including respiratory distress. ARDS-003 also outperformed the antiviral drug...
這些研究探索了ARDS-003目的:提高人源化ACE2小鼠模型中SARS-CoV-2感染後的生存指標。在SARS-CoV-2感染的動物中...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論